Answers are grounded in this paper and cite their sources.
Objective This study aimed to systematically characterize the knowledge structure, research evolution, hotspots, and emerging frontiers of gut probiotics in metabolic dysfunction-associated steatotic liver disease (MASLD), and to assess the cross-database consistency of the identified patterns, thereby providing a bibliometric basis to inform future mechanistic investigation and clinically oriented research. Methods A total of 1,157 eligible publications from 2003 to 2026 were identified from the Web of Science Core Collection (WoSCC) and analyzed using CiteSpace, VOSviewer, Bibliometrix, and SCImago Graphica. PubMed and Scopus were independently searched on the same date and used as complementary comparison databases for cross-database consistency assessment rather than for data pooling. Results Publication output increased markedly after 2011, with China contributing the largest number of publications, while the United States of America (USA) and Italy also showed substantial research activity and citation impact. The field exhibited extensive international collaboration and a multidisciplinary knowledge structure involving hepatology, gastroenterology, nutrition, microbiology, and molecular biology. Keyword and co-citation analyses showed that research attention has progressively shifted from obesity, insulin resistance, endotoxemia, and intestinal barrier dysfunction toward the gut–liver axis, microbial metabolites, MASLD and Metabolic dysfunction-associated steatohepatitis (MASH), precision medicine, and more targeted probiotic interventions. Annual publication trends were highly consistent across WoSCC, PubMed, and Scopus, with pairwise Pearson correlations ranging from 0.995 to 0.998. Strong agreement also persisted for year-to-year changes and detrended publication counts, and the results remained stable after exclusion of the incomplete 2026 observation. Author keyword patterns also showed strong cross-database agreement, supporting the stability of the major thematic findings. Conclusion Research on MASLD and gut probiotics is progressing from broad associations between dysbiosis and metabolic liver disease toward mechanistic investigation and more precise probiotic strategies. Future studies should prioritize strain-specific effects, patient stratification, mechanistic biomarkers, and well-designed clinical trials to better inform future clinical translation.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: